Quote:

---

Cytodyn doesn’t have enough $ resources to finish both mssCRC trial and inflammation study. For that reason, priority should be given imo to using available $ to complete mssCRC trial and obtaining results.

---

Cytodyn agreed to do the inflammation trial to keep the FDA happy. I guarantee it's low priority until we get revenue. It would be nice to do so we can prove the downstream effects of leronlimab, but it matters little if we don't have the cash for further trials.